COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,786 Articles (22,946 medRxiv, 8,840 bioRxiv)

Most recent first Previous |  Page 149: Articles 1481-1490  | Next

Seasonal forcing and waning immunity drive the sub-annual periodicity of the COVID-19 epidemic
Rubin, I. N., Bushman, M., Lipsitch, M., Hanage, W. P.
10.1101/2025.03.05.25323464 — Posted: 2025-03-06
Calculating the probability that a previously susceptible individual is infected as a function of time following exposure to SARS-CoV-2
Thomas, A., Khader, K., Hersh, A. L., Samore, M. H.
10.1101/2025.03.05.24317200 — Posted: 2025-03-06
Post-vaccination SARS-CoV-2 neutralizing antibodies in pregnant women receiving biologics for inflammatory bowel disease
Leet, D., Jin, J., Craik, C. S., Kattah, M. G., Long, M. D., Mahadevan, U.
10.1101/2025.03.05.25323433 — Posted: 2025-03-06
Effect of the COVID-19 pandemic on the post-Ebola referral system in Sierra Leone: A descriptive analysis
samura, s., Youkee, D., Molleh, B., Kanu, J. S., Vandy, M. J., Koedoyoma, S., Bangura, T. M., Lansana, H. K., Musa, I. F., Kabba, M. S., Kenneh, S. M., Chan, A. K., Mishra, S., Sevalie, S., Lakoh, S.
10.1101/2025.03.05.25323450 — Posted: 2025-03-06
Adherence to preventive behaviors related to Covid-19 in Taiwan in 2020-2021: a population-based follow-up survey
Wu, C.-Y., Lan, C.-C., Jian, S.-W., Yang, C.-C., Hsu, W.-C., Chen, P.-C., Chang, S.-S., Lin, H.-H.
10.1101/2025.03.04.25323269 — Posted: 2025-03-06
Investigation of the Mechanism of Action of JinHuangJieDu against SARS-CoV-2 Infection and Inflammation Based on Network Pharmacology and Experimental Validation
Zhanqun, Y., Jian, W., MengZhu, Z., Yuan, X., LiTing, Z., YiHeng, Y., Hua, J., Long, C., Jian, L.
10.1101/2025.03.05.641771 — Posted: 2025-03-06
DMBT1 promotes SARS-CoV-2 infection and its SRCR-derived peptide inhibits SARS-CoV-2 infection
Zhu, C., Wang, Z., Pan, Z., Mai, X., Chen, Y., Zhang, W., Zhao, P., Tang, H., Zhang, R., Zhou, D.
10.1101/2025.03.06.641801 — Posted: 2025-03-06
The coronavirus helicase synergizes with the viral RNA polymerase to enable rapid RNA synthesis through duplex RNA
America, P., BERA, S. C., Das, A., Anderson, T. K., Marecki, J. C., Papini, F. S., Arnold, J. J., Kirchdoerfer, R., Cameron, C. E., Raney, K. D., Depken, M., Dulin, D.
10.1101/2025.03.05.641625 — Posted: 2025-03-06
Synergistic interference with SARS-CoV-2 replication by Molnupiravir-derived N4 hydroxycytidine and inhibitors of CTP synthetase
Stegmann, K. M., Dickmanns, A. M., Fuchs, H. L., Scheibner, D., Mohl, B.-P., Moeselaken, F., Reineking, W., Stoerk, T., Volz, A., Beer, P., Parker, A., Pilchova, V., Meyer zu Natrup, C., von Koeckritz-Blickwede, M., Baumgaertner, W., Balkema-Buschmann, A., Dobbelstein, M.
10.1101/2025.03.06.641790 — Posted: 2025-03-06
No baby boom of social mammals in European zoos resulting from COVID-19 lockdowns
Maille, A., Garcia, C., Colchero, F., Lemaitre, J.-F., Pavard, S.
10.1101/2025.03.05.641480 — Posted: 2025-03-05

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).